Quest Diagnostics, a leading provider of diagnostic information services, has completed its previously announced acquisition of select clinical testing assets from Spectra Laboratories, a wholly owned subsidiary of Fresenius Medical Care. Spectra is a major provider of renal-specific laboratory testing services in the U.S.

With this acquisition, Quest will now offer dialysis-related clinical testing services to independent dialysis clinics that were previously served by Spectra. Additionally, Quest expects to finalize the acquisition of select dialysis-related water testing assets by the end of 2025.

As part of a separate laboratory services agreement, Quest will begin providing comprehensive dialysis-related lab services later this month for Fresenius Medical Care’s U.S. dialysis centers, which serve about 200,000 patients annually. This transition is expected to scale up over the coming months and be completed by early 2026.

Through this collaboration, dialysis clinics and their patients will gain access to Quest’s clinical expertise and innovations in chronic kidney disease (CKD) testing. By leveraging multiple Quest labs across the country, test result turnaround times are expected to improve due to reduced transport times. Quest also aims to optimize its lab network utilization by performing tests during lower-volume daytime hours.

CKD affects approximately 35.5 million Americans, or 14% of the population, and is one of the most prevalent and costly chronic illnesses in the U.S. Yet up to 90% of adults with CKD remain undiagnosed. Once CKD progresses to end-stage kidney disease (ESKD), patients typically require dialysis or transplant. Dialysis involves regular lab testing to monitor disease progression and water testing to ensure treatment safety.